Menno V. Huisman, MD, PhD, John Fanikos, RPh, MBA

Slides:

Advertisements

Similar presentations

Low-Dose Aspirin in Patients with Stable Cardiovascular Disease: A Meta-analysis Jeffrey S. Berger, MD, MS, David L. Brown, MD, Richard C. Becker, MD The.

Advertisements

Recognition and First-Line Treatment of Anaphylaxis

Paul D. Stein, MD, Fadi Matta, MD, Mary J. Hughes, DO

Steven Baroletti, PharmD, MBA, Shelley Hurwitz, PhD, Nicole A. S

Bleeding Toes in Diabetic Neuropathy

Joanne van Ryn, PhD, Lawrence Baruch, MD, Andreas Clemens, MD

Amay Parikh, MD, MBA, MS, Kunal Gupta, MD, MBA, Alan C

Wayne S. Dysinger, MD, MPH, James M. Pappas, MD, MBA

What Started This? Debilitating Longitudinally-extensive Myelitis

Luigi F. Meneghini, MD, MBA The American Journal of Medicine

New Developments in Insulin Therapy for Type 2 Diabetes

David D. McManus, MD, ScM, Wei Huang, MS, Kunal V

Richard V. Milani, MD, Carl J. Lavie, MD, Robert M

Comparative Effectiveness Research and Medical Informatics

Bleeding Toes in Diabetic Neuropathy

Recurrent infarction causes the most deaths following myocardial infarction with left ventricular dysfunction Stein Ørn, MD, John G.F. Cleland, MD, Matti.

Samy Suissa, PhD, Abbas Kezouh, PhD, Pierre Ernst, MD, MSc

Karlyn A. Martin, MD, Craig R. Lee, PharmD, PhD, Timothy M

Truman J. Milling, MD, Scott Kaatz, DO, MSc

Jason Thomas, MD, Erica Saenz, MD, Paul Haggerty, MD

Systematic Review and Meta-analysis of Adverse Events of Low-dose Aspirin and Clopidogrel in Randomized Controlled Trials Kenneth R. McQuaid, MD, Loren.

Athena Philis-Tsimikas, MD The American Journal of Medicine

“Reversing Direct Oral Anticoagulants”

Online Educational Video Improves Bowel Preparation and Reduces the Need for Repeat Colonoscopy Within Three Years Umar Hayat, MD, Peter J.W. Lee, MBChB,

SAMe-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation Pilar Gallego, MD, PhD, Vanessa Roldán,

Effect of Aspirin on Mortality in the Primary Prevention of Cardiovascular Disease Nina Raju, MD, MsC, Magdalena Sobieraj-Teague, MBBS, Jack Hirsh, MD,

John Fanikos, RPh, MBA, Allison E. Burnett, PharmD, Charles E

New oral anticoagulants—what the cardiothoracic surgeon needs to know

Steven Baroletti, PharmD, MBA, Shelley Hurwitz, PhD, Nicole A. S

Epidemiology of Myelodysplastic Syndromes

Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus C. Thorborg,

Prevention of Anaphylaxis: The Role of the Epinephrine Auto-Injector

Evidence Supporting Idarucizumab for the Reversal of Dabigatran

Baffling Tachycardia The American Journal of Medicine

John Fanikos, RPh, MBA, Amanda Rao, BS, Andrew C

The Impact of the Host on Fungal Infections

David D. McManus, MD, ScM, Wei Huang, MS, Kunal V

The Role of Quality Improvement and Patient Safety in Academic Promotion: Results of a Survey of Chairs of Departments of Internal Medicine in North America

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Medical professionalism and the generation gap

Jane S. Saczynski, PhD, Darleen Lessard, MS, Frederick A

The Reply The American Journal of Medicine

James E. Novak, Khalid Alamiri, Jerry Yee

Notifications Received by Primary Care Practitioners in Electronic Health Records: A Taxonomy and Time Analysis Daniel R. Murphy, MD, MBA, Brian Reis,

Idarucizumab, a Specific Reversal Agent for Dabigatran: Mode of Action, Pharmacokinetics and Pharmacodynamics, and Safety and Efficacy in Phase 1 Subjects

Hereditary Angioedema: New Findings Concerning Symptoms, Affected Organs, and Course Konrad Bork, MD, Gabriele Meng, MD, Petra Staubach, MD, Jochen Hardt,

Carlos Aguilar, MD, Valentin del Villar, MD

James H. O'Keefe, MD, Robert Vogel, MD, Carl J

Truman J. Milling, MD, Alex C. Spyropoulos, MD

Repeated Hemoglobin A1C Ordering in the VA Health System

Resistant Hypertension and the Pivotal Role for Mineralocorticoid Receptor Antagonists: A Clinical Update 2016 Murray Epstein, MD, Daniel A. Duprez,

Insomnia in the Elderly: Cause, Approach, and Treatment

John-Michael Gamble, BScPharm, MSc, Dean T. Eurich, PhD, Thomas J

Hypothermia in Systemic Lupus Erythematosus

A Review of Learner Impact on Faculty Productivity

A Post-cure Complication

Plasma Lactescence in Acute Pancreatitis

Risk of Falls and Major Bleeds in Patients on Oral Anticoagulation Therapy Jacques Donzé, MD, MSc, Carole Clair, MSc, MD, Balthasar Hug, MD, MBA, MPH,

Primary Care Management of Skin Abscesses Guided by Ultrasound

Rebecca D. Chason, Joan S. Reisch, PhD, Don C. Rockey, MD

Magnitude of Venous Thromboembolism Risk in US Hospitals: Impact of Evolving National Guidelines for Prevention of Venous Thromboembolism Wei Huang,

Direct Observation of Residents: A Model for an Assessment System

The Reply The American Journal of Medicine

Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis Karl-Georg Fischer, M.D., Andreas van.

Falls in Older Adults: Risk Assessment, Management and Prevention

Hospital Costs of Acute Pulmonary Embolism

Invasive Mycoses: Diagnostic Challenges

Toward a More Responsible News Media

David Tian, MD, Ram Jhingan Mohan, MD, Gary Stallings, MD

Incretin Therapies: Effects Beyond Glycemic Control

Presentation transcript:

Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols Menno V. Huisman, MD, PhD, John Fanikos, RPh, MBA The American Journal of Medicine Volume 129, Issue 11, Pages S89-S96 (November 2016) DOI: 10.1016/j.amjmed.2016.06.010 Copyright © 2016 Terms and Conditions

Figure Suggested algorithm for the management of dabigatran-treated patients who experience a bleeding episode or who require urgent surgery/invasive procedures. *Administer two 50-mL vials of idarucizumab (each containing 2.5 g) intravenously. In rare cases when dabigatran-related anticoagulation persists after a course of idarucizumab, and bleeding continues in the patient, a second 5 g dose of idarucizumab may be considered. aPTT = activated partial thromboplastin time; dTT = diluted thrombin time; TT = thrombin time. Reproduced with permission from: Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: the antidote for reversal of dabigatran. Circulation. 2015;132:2412-2422.26 The American Journal of Medicine 2016 129, S89-S96DOI: (10.1016/j.amjmed.2016.06.010) Copyright © 2016 Terms and Conditions